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Abstract
Background: CD4 cell count is a strong predictor of the subsequent risk of AIDS or death in HIV-infected patients initiating
combination antiretroviral therapy (cART). It is not known whether the rate of CD4 cell decline prior to therapy is related to
prognosis and should, therefore, influence the decision on when to initiate cART.
Methods and Findings: We carried out survival analyses of patients from the 23 cohorts of the CASCADE (Concerted Action
on SeroConversion to AIDS and Death in Europe) collaboration with a known date of HIV seroconversion and with at least
two CD4 measurements prior to initiating cART. For each patient, a pre-cART CD4 slope was estimated using a linear mixed
effects model. Our primary outcome was time from initiating cART to a first new AIDS event or death. We included 2,820
treatment-naı¨ve patients initiating cART with a median (interquartile range) pre-cART CD4 cell decline of 61 (46–81) cells/ml
per year; 255 patients subsequently experienced a new AIDS event or death and 125 patients died. In an analysis adjusted
for established risk factors, the hazard ratio for AIDS or death was 1.01 (95% confidence interval 0.97–1.04) for each 10 cells/
ml per year reduction in pre-cART CD4 cell decline. There was also no association between pre-cART CD4 cell slope and
survival. Alternative estimates of CD4 cell slope gave similar results. In 1,731 AIDS-free patients with .350 CD4 cells/ml from
the pre-cART era, the rate of CD4 cell decline was also not significantly associated with progression to AIDS or death (hazard
ratio 0.99, 95% confidence interval 0.94–1.03, for each 10 cells/ml per year reduction in CD4 cell decline).
Conclusions: The CD4 cell slope does not improve the prediction of clinical outcome in patients with a CD4 cell count
above 350 cells/ml. Knowledge of the current CD4 cell count is sufficient when deciding whether to initiate cART in
asymptomatic patients.
Please see later in the article for the Editors’ Summary.
Citation: Wolbers M, Babiker A, Sabin C, Young J, Dorrucci M, et al. (2010) Pretreatment CD4 Cell Slope and Progression to AIDS or Death in HIV-Infected Patients
Initiating Antiretroviral Therapy—The CASCADE Collaboration: A Collaboration of 23 Cohort Studies. PLoS Med 7(2): e1000239. doi:10.1371/journal.pmed.1000239
Academic Editor: Steven G. Deeks, San Francisco General Hospital, United States of America
Received July 28, 2009; Accepted January 22, 2010; Published February 23, 2010
Copyright:  2010 Wolbers et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: CASCADE has been funded through grants BMH4-CT97-2550, QLK2-2000-01431, QLRT-2001-01708, and LSHP-CT-2006-018949 from the European
Union. MW and HCB are supported by research grants from sante´suisse and the Gottfried and Julia-Bangerter-Rhyner Foundation. The funders had no role in
study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: HCB received travel grants, honoraria, and unrestricted research grants from various pharmaceutical companies including,
GlaxoSmithKline, Bristol-Myers-Squibb, Gilead, Roche, Abbott, Tibotec, and Boehringer-Ingelheim. The research of MW, JY, and HCB is supported by unrestricted
grants from sante´suisse and the Gottfried and Julia Bangerter-Rhyner-Foundation. The Medical Research Council, Clinical Trials HIV Group, led by AB, received
donated drugs and/or financial support for substudies from the following pharmaceutical companies: Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Cipla,
Gilead, Tibotec, Roche, GlaxoSmithKline, Indevus, Merck, Novartis, Sanofi Pasteur, and Virco. KP also received honorarium from Tibotec. CS has received funding
for research, teaching, and consultancy from several pharmaceutical companies (GlaxoSmithKline, Gilead Sciences, Bristol-Myers Squibb, and Tibotec) over the last
few years. CM received travel grants and honoraria from: GlaxoSmithKline, Bristol-Myers-Squibb, Gilead, Roche, Abbott, Tibotec, and Boehringer-Ingelheim. The
research of CM is supported by Istituto Superiore di Sanita`.
Abbreviations: cART, combination antiretroviral therapy, CASCADE, Concerted Action on SeroConversion to AIDS and Death in Europe.
* E-mail: mwolbers@oucru.org
" Membership of the CASCADE Collaboration is provided in the Acknowledgments.
PLoS Medicine | www.plosmedicine.org 1 February 2010 | Volume 7 | Issue 2 | e1000239
Introduction
CD4 cell count is a strong predictor of the subsequent risk of
AIDS or death in both untreated HIV-infected individuals and in
those initiating combination antiretroviral therapy (cART) [1–5].
It is, therefore, a key marker for clinicians when deciding whether
to initiate cART in asymptomatic patients. Current guidelines
recommend treatment of asymptomatic patients before [6] or
when their CD4 cell count drops below 350 cells/ml [7,8]. The US
Department of Health and Human Services (DHHS) panel also
gives a moderate to strong recommendation to initiate cART in
patients with a CD4 cell count between 350 and 500 cells/ml and
is divided on whether to favour cART initiation in patients with
CD4 cell count .500 cells/ml [7]. In addition, the International
AIDS Society-USA (IAS-USA) guidelines suggest clinicians should
consider cART initiation given a rapid CD4 cell count decline
(.100 cells/ml per year) regardless of CD4 cell count [6], and the
European AIDS Clinical Society (EACS) guidelines suggest cART
should be considered given a CD4 cell count decline .50–
100 cells/ml per year in patients with 350–500 CD4 cells/ml [8].
In the absence of evidence from randomised controlled trials,
large collaborative cohort studies have used different modelling
approaches to estimate the effect of initiating, rather than
deferring, cART at different CD4 cell levels. The most recent
data from cohort studies indicate that initiating cART at a CD4
cell count above 350 cells/ml may reduce the risk of AIDS and
death [9,10]. However, it is not known whether the dynamics of
CD4 cell depletion, represented by the pre-cART CD4 cell slope,
carry additional prognostic value for outcomes after cART
initiation. Of note, in untreated patients the rate of CD4 cell
decline explains only 3% and 7% of the variability in the time to
AIDS and death respectively, and there is only a weak correlation
between an initial viral load and the subsequent rate of CD4 cell
decline [1,11].
We consider whether CD4 cell decline is related to prognosis in
patients initiating cART as well as those not treated with cART,
and whether it is, therefore, relevant to the decision on whether to
initiate therapy in asymptomatic patients. We use data from
CASCADE (Concerted Action on SeroConversion to AIDS and
Death in Europe), a large collaborative cohort study of individuals
with documented evidence of the date of their HIV seroconversion
[12,13].
Methods
Patients and Procedures
CASCADE is a collaboration of 23 cohorts: 20 cohorts from
Europe, two cohorts from Australia, and one cohort from Canada
[13]. All cohorts received approval from their individual ethics
review boards except for the Danish cohort, which received approval
from the National Data Registry Surveillance Agency (because
Danish law allowed collection and pooling of anonymised clinical
data with approval from this agency alone). Two ethics review
boards deemed their cohort participants exempt from providing
signed informed consent. Signed informed consent was obtained
from all others. Approval was also given by all ethics review boards
to pool anonymised data for analyses and dissemination.
Each cohort provides data on HIV-1 infected individuals with a
well-known date of HIV seroconversion. Our analysis was based
on the 2008 update of CASCADE data. For most (88%) of the
19,615 patients in this update, the date of HIV seroconversion was
estimated as the midpoint between the first positive HIV antibody
test and the last documented negative HIV antibody test result.
The time difference between the first positive and last negative
HIV antibody test was less than 3 y in all cases, and less than 2 y
or 1 y for 87% and 61% of such estimates, respectively. For the
remaining patients, the date of seroconversion was based either on
laboratory evidence of seroconversion (9%)—real-time PCR
positivity in the absence of HIV antibodies or antigen positivity
with fewer than four bands on a Western blot; on the date of a
seroconversion illness (and an earlier documented negative HIV
test at most 3 y apart) (2%); or the most likely date of an infected
factor VIII concentrate infusion for haemophiliacs (1%).
Our main study population comprised all treatment-naı¨ve
individuals who started cART in 1996 or later, aged at least 16 y
at the time of seroconversion, with a viral load and CD4 cell count
measured either at cART initiation or within 91 d prior to
initiation, and with at least one earlier CD4 cell count (and an
interval between the two measurements of at least 3 mo). cART
was defined as either a single or boosted protease inhibitor (PI)-
based regimen or a non-nucleoside reverse transcriptase inhibitor
(NNRTI)-based regimen in combination with at least two
nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs),
or a triple NRTI regimen.
Our primary endpoint was the time from cART initiation to a
first new AIDS event or death. Reoccurrence of previous
opportunistic infections were not deemed to be new AIDS events
as it would be difficult to distinguish an ongoing disease from a
relapse [14]. Patients without an event were censored at the date of
their last clinic visit. As a secondary endpoint, we analysed overall
survival.
In a supplementary analysis we included patients not treated
with cART during the period 1989 to 1995 (i.e., before the
introduction of cART) [9]. The study population for this
supplementary analysis comprised all patients with a recorded
CD4 cell count in the year 1993, with no prior AIDS event and
with at least one prior CD4 cell count recorded between 1989 and
1993. Baseline for the survival analysis was the date of the patient’s
last recorded CD4 cell count in 1993 and the time-to-event
endpoint was defined as the time from baseline until AIDS or
death. Patients without an AIDS event or death before December
31, 1995 were censored at this date (or at their last clinical visit if
that visit was before this date). The supplementary analysis
included patients receiving mono- and dual-antiretroviral therapy.
In a sensitivity analysis, we excluded patients who initiated any
antiretroviral therapy in 1993 or earlier and censored the time-to-
event endpoint at the time of initiation of antiretroviral therapy if
therapy was initiated in 1994 or 1995.
Statistical Methods
We investigated whether the rate of CD4 cell decline prior to
cART initiation (the ‘‘pre-cART CD4 cell slope’’) is a prognostic
factor for a new AIDS event or death. Univariate and adjusted
effects were estimated using Cox proportional hazards models. For
the latter, we adjusted for established predictors from the ART
Cohort Collaboration risk model [2–4]: CD4 cell count, viral load
(log-transformed) and age at cART initiation, a previous AIDS
event, and HIV transmission through injection drug use.
Adjustment for CD4 cell count (categorized as ,100, 100 to
,200, 200 to ,350 and $350 cells/ml) and transmission through
injection drug use was by stratification. We assessed the
discrimination of 5-y predictions from these Cox models using
the c index [15]. The analysis was performed both for all patients
satisfying our inclusion criteria as well as for the subgroup of
patients with a CD4 cell count at cART initiation .350 cells/ml.
Pre-cART CD4 cell slopes were estimated as best linear
unbiased predictions using all available CD4 cell measurements
from seroconversion until cART initiation and a linear mixed
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model with a patient-specific random intercept and a random
slope for time since seroconversion. In a series of sensitivity
analyses, we considered alternative estimates of CD4 cell slope
using three different mixed models, a joint model for both CD4
cell count and time to cART initiation [16], and separate least
squares estimates for each patient. Of the three different mixed
models, the first excluded CD4 cell counts less than 6 mo following
the first positive HIV test; the second included only CD4 cell
counts within 2 y before cART initiation; and the third included
only patients who seroconverted from 1996 onwards. The joint
model allowed for the possibility of informative censoring if low
pre-cART CD4 cell counts were often missing because individuals
with low counts typically initiate cART. By jointly modelling
longitudinal counts with a mixed model and time to cART
initiation with a survival model, the survival component of this
joint model acted as a missing data mechanism. The survival
component of our joint model included covariates for both the
date of seroconversion and cohort to account for varying
treatment guidelines over time and between cohorts.
The proportion of patients with a CD4 decline of $100 cells/ml
per year was calculated based on slope estimates from a linear
mixed model or least squares. These estimates were compared to a
simple calculation of a patients’ CD4 cell slope at cART initiation
using linear interpolation between the last two CD4 cell counts
that were at least 6 mo apart.
In addition, we examined whether the assumption of a constant
patient-specific pre-cART CD4 slope was supported by the data
by fitting a more general model for CD4 trajectories with a
random (patient-specific) intercept, a fixed (population) slope, an
integrated Ornstein-Uhlenbeck process, and measurement error
[17,18]. This model has a parameter a that measures how stable
within-patient slopes are over time. When a is zero, the model is
equivalent to a random effects model with a constant patient-
specific CD4 slope; when a takes a large (positive) value, the model
implies that patient-specific CD4 trajectories are highly variable
over time, randomly fluctuating around a population slope
according to a Brownian motion process. This model was found
to better fit our data than alternative nonlinear models of CD4 cell
decline (see Text S1).
All formal model comparisons were based on square-root–
transformed CD4 cell counts as this improved the fit of all
models. However, we report CD4 cell slope estimates and effect
measures of the CD4 cell slope on outcome on the basis of models
of untransformed data as rates of CD4 cell decline on the original
scale are much easier to interpret than estimates on the square-
root scale. Analyses on the original and the square-root scale lead
to highly correlated CD4 cell slope estimates and to very similar
conclusions regarding the influence of CD4 cell slope on
outcomes in Cox regression analyses. As an example, slope
estimates based on the primary mixed effects model with and
without prior square-root transformation showed a Spearman
rank correlation of 0.94.
In the supplementary analysis of data from the pre-cART era,
CD4 slopes were estimated as for the main analysis (i.e., with a
linear mixed effects model with a random intercept and slope).
The Cox regression model for the time to AIDS or death was
adjusted for the CD4 cell count and age at baseline, and HIV
transmission through injection drug use. Adjustment for CD4 cell
count and HIV transmission was by stratification as for the
primary analysis. We could not adjust for HIV viral load as this
was seldom measured in the pre-cART era.
All analyses were carried out with the statistical software R
version 2.8.0 [19]; the contributed R package JM was used for
joint modelling [20].
Results
Of 6,603 treatment-naı¨ve patients initiating cART since 1996
and aged at least 16 y at seroconversion, 2,820 patients fulfilled
our inclusion criteria. Patients were excluded because they had
fewer than two recorded CD4 cell counts prior to cART initiation
(n = 3,177) or were lacking a CD4 cell count (n = 54), a viral load
measurement (n = 303), or both (n = 249) within 91 d prior to
cART initiation. Among those included, the median time from
seroconversion to initiating cART was 3.5 y; cART was initiated
at a median age of 36 y and with a median CD4 cell count of
289 cells/ml (Table 1). Excluded patients initiated cART earlier
(median of 0.8 y from seroconversion to initiating cART), at a
higher CD4 cell count (median 360 cells/ml) or were treated for
seroconversion illness.
Estimates from the linear mixed effects model gave a median
(interquartile range [IQR]) pre-cART CD4 cell decline of 61
(46–81) cells/ml per year and 13% of individuals had a decline
.100 cells/ml per year. Separate least squares estimates for each
patient gave a median pre-cART CD4 decline of 74 (31–145) cells/
ml per year and 38% of individuals had a decline .100 cells/ml per
year. Finally, if slopes were estimated by interpolating the last two
CD4 measurements at least 6 mo apart before cART initiation,
median (IQR) decline was 114 (32–229) cells/ml per year and 54%
of individuals had a decline .100 cells/ml per year.
During 10,296 person-years of follow-up (with a median follow-
up of 3.2 y per patient), 255 patients experienced the primary
endpoint of a new AIDS event or death (with 92 deaths). When
cross-classified by the quartiles of pre-cART CD4 slope, these 255
events were partitioned into 71, 60, 56, and 68 events respectively.
A total of 125 patients died during follow-up.
In an unadjusted Cox model, the hazard ratio for AIDS or
death was 0.99 (95% confidence interval [CI] 0.95–1.02) for each
10 cells/ml per year reduction in pre-cART CD4 cell decline
(Table 2). The discrimination of this variable (the c index) was
0.52; lower than any individual component in the ART Cohort
Collaboration risk prediction model (with c indices ranging from
0.56 for age to 0.64 for CD4 cell count). In an adjusted Cox
model, the hazard ratio for AIDS or death was 1.01 (95% CI
0.97–1.04) for each 10 cells/ml per year reduction in pre-cART
CD4 cell decline, and multivariate Cox models with and without
pre-cART CD4 slope had identical c indices of 0.70. There was
also no association between pre-cART CD4 slope and survival
(Table 2). Sensitivity analyses using alternative estimates of pre-
cART CD4 cell slope gave consistent results in adjusted Cox
models for the time to a new AIDS event or death, with p-values
ranging from 0.24 to 0.88. There was also no evidence of an
association of pre-cART CD4 slope and progression to AIDS or
death when we restricted our analysis to 961 patients with a CD4
cell count .350 cells/ml at cART initiation (Table 2) or when the
pre-cART CD4 slope was entered as a binary covariate ($100
versus ,100 cells/ml decline per year) instead of as a continuous
covariate (unpublished data).
Nonlinear models for pre-cART CD4 cell decline fitted the data
significantly better than the linear models discussed above and the
model based on an integrated Ornstein-Uhlenbeck process led to
the best fit (see Text S1). This model gave a 95% CI for the
parameter a from 36 to infinity, which corresponds to highly
variable within-patient rates of CD4 cell decline over time, so that
the correlation between a patient’s current CD4 cell slope and
their CD4 cell slope in 6 mo time is estimated to be essentially zero
[18].
A total of 3,078 patients were included in the supplementary
analysis using data from the pre-cART era. Baseline characteristics
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are displayed in Table 3. There was a significant association
between CD4 cell slope and the 2-y risk of AIDS events or deaths
in these cART-naive patients with an adjusted hazard ratio of 0.96
(95% CI 0.94–0.98) for each 10 cells/ml per year reduction in
CD4 cell decline. However, the CD4 cell slope did not
significantly affect the progression to AIDS or death when the
analysis was restricted to 1,731 patients with CD4 .350 cells/ml
at baseline (hazard ratio 0.99, 95% CI 0.94–1.03, for each
10 cells/ml per year reduction in CD4 cell decline; Table 4). By
contrast, CD4 cell count and age remained highly significant
predictors in this subgroup. The sensitivity analysis that excluded
all patients receiving mono- or dual-antiretroviral therapy was
based on 1,797 patients with a median CD4 cell count of
480 cells/ml at baseline, a median CD4 cell slope of 247 cells/ml
per year, and 137 subsequent AIDS events or deaths. The adjusted
hazard ratio of the CD4 cell slopes on AIDS events or deaths was
0.97 (95% CI 0.93–1.01; p = 0.15) for each 10 cells/ml per year
reduction in CD4 cell decline if patients were included regardless
of CD4 cell count and 0.98 (95% CI 0.92–1.04; p = 0.48) in 1,346
patients with CD4 cell count .350 cells/ml at baseline.
Discussion
We found no evidence that knowledge of pre-cART CD4 cell
slope improves the prediction of the risk of a new AIDS event or
death in our analysis of 2,820 treatment-naı¨ve patients who then
started cART. The 95% CI for the adjusted hazard ratio of 0.97–
1.04 for each 10 cells/ml per year reduction in pre-cART CD4 cell
decline is sufficiently narrow to exclude a large effect.
Our study only included patients with a known date of
seroconversion. In a general population of HIV-infected individ-
uals, patients presenting with an unknown duration of infection
will have even fewer CD4 cell measurements prior to initiating
cART making it more difficult to estimate a reliable pre-cART
CD4 cell slope for such patients [21,22]. We estimated CD4 slopes
from untransformed CD4 cell counts using a linear mixed model
because this approximates how a physician might intuitively
estimate the CD4 cell slope for a patient: first estimate the patient’s
slope by eye or using standard linear regression but then adjust
that estimate towards the population slope if only few CD4 cell
counts are available for that patient. We also found similar
prognostic performance on the basis of alternative estimates of the
CD4 cell slope.
However, the proportion of patients with a CD4 cell decline
.100 cells/ml per year varied from 13% to 54%, depending on
the method used to estimate a patient’s CD4 cell slope. The
variability of slope estimates, and hence the prevalence of patients
with a rapid CD4 cell decline, decreased markedly as more
information was included in the calculation of a patient’s slope.
Only two CD4 cell counts (the interpolation of the last two
measurements) gave highly variable slope estimates and a high
percentage of patients with a rapid decline, using all measurements
for each patient (least-squares estimation) was intermediate, while
adding background information on the distribution of slopes in the
general population (mixed model estimation) gave the least
variable slope estimates and the lowest percentage of patients
with a rapid decline. Current treatment guidelines give explicit
thresholds for CD4 cell count decline, from 50 to 100 cells/ml per
Table 1. Characteristics of 2,820 treatment-naı¨ve patients from the CASCADE collaboration initiating cART in 1996 or later.
Characteristic Summary Statistic: n (%) or Median (Interquartile Range)
All Patients
(n=2,820)
Patients with .350 CD4
Cells/ml at cART Initiation (n=961)
Female 578 (20%) 215 (22%)
Age at cART initiation (y) 36 31–43 34 30–41
Most likely source of infection
Sex between men and women 734 (26%) 249 (26%)
Sex between men and men 1,669 (59%) 545 (57%)
Injecting drug use 247 (9%) 93 (10%)
Other/unknown 170 (6%) 74 (8%)
Type of first cART
Boosted PI 705 (25%) 171 (18%)
Single PI 680 (24%) 358 (37%)
NNRTI 1,166 (41%) 316 (33%)
Triple NRTI 269 (10%) 116 (12%)
Prior AIDS 216 (8%) 50 (5%)
Time between last negative and first positive HIV test (y) 0.82 0.35–1.49 0.78 0.38–1.41
Time from seroconversiona to cART initiation (y) 3.52 1.86–6.41 3.11 1.63–5.84
Viral load (log10 copies/ml) at cART initiation 4.78 4.11–5.25 3.66 4.54–5.05
CD4 cell count (cells/ml) at cART initiation 289 206–398 468 393–580
Number of CD4 measurements before cART initiation 7 4–12 6 4–10
Estimated pre-cART CD4 slope (cells/ml per year)b 261 281 to –46 258 274 to –37
aMidpoint between last negative and first positive test for 2,588 patients; date of laboratory evidence of seroconversion or seroconversion illness for the remaining
patients.
bPredictions from a linear mixed model with a random intercept and a random slope for the covariate time since seroconversion.
PI, protease inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, reverse transcriptase inhibitor.
doi:10.1371/journal.pmed.1000239.t001
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Table 2. Prognostic strength of the pre-cART CD4 slope for the prediction of clinical outcomes in 2,820 treatment-naı¨ve patients
from the CASCADE collaboration initiating cART in 1996 or later.
Outcome and Type of Summary
All Patients
(n=2,820)
Patients with .350 CD4
cells/ml at cART Initiation (n=961)
Outcome: time to new AIDS event or death
Number of events 255 (9%) 9 (9%)
Event rate per 100 patient-years of follow-up (95% CI) 2.48 (2.17–2.78) 2.04 (1.61–2.46)
Unadjusted effect of pre-cART CD4 slope on outcome
HR for +10 cells/ml per year higher slope (95% CI) 0.99 (0.95–1.02); p = 0.39 0.99 (0.94–1.05); p= 0.85
Discrimination (c index) 0.52 — 0.55 —
Adjusted effect of pre-cART CD4 slopea
HR for +10 cells/ml per year higher slope (95% CI) 1.01 (0.97–1.04); p= 0.65 1.02 (0.96–1.08); p= 0.48
Discrimination (c index) of model without CD4 slope 0.70 — 0.65 —
Discrimination (c index) of model with CD4 slope 0.70 — 0.65 —
Outcome: time to death
Number of events 125 (4%) 47 (5%)
Event rate per 100 patient-years of follow-up (95% CI) 1.12 (0.93–1.32) 1.00 (0.71–1.28)
Unadjusted effect of pre-cART CD4 slope on outcome
HR for +10 cells/ml per year higher slope (95% CI) 1.01 (0.96–1.06); p= 0.83 0.97 (0.90–1.05); p= 0.41
Discrimination (c index) 0.50 0.62
Adjusted effect of pre-cART CD4 slopea
HR for +10 cells/ml per year higher slope (95% CI) 1.01 (0.96, 1.06); p= 0.65 0.98 (0.91–1.05); p= 0.52
Discrimination (c index) of model without CD4 slope 0.73 — 0.69 —
Discrimination (c index) of model with CD4 slope 0.73 — 0.72 —
The pre-cART CD4 slope was estimated by a linear mixed model with a random intercept and a random slope for time since seroconversion.
aAdjusted for established predictors from the ART Cohort Collaboration risk model: CD4 cell count, viral load (log-transformed) and age at cART initiation, a previous
AIDS event, and HIV transmission through injection drug use.
HR, hazard ratio.
doi:10.1371/journal.pmed.1000239.t002
Table 3. Characteristics of 3,078 AIDS-free patients from the CASCADE collaboration with a CD4 cell count in 1993 and at least one
prior CD4 cell count.
Characteristic Summary Statistic - n (%) or Median (Interquartile Range)
All Patients
(n=3,078)
Patients with .350
CD4 cells/ml at Baseline (n=1,731)
Female 677 (22%) 411 (24%)
Age at baselinea (y) 32 28–38 31 27–37
Most likely source of infection
Sex between men and women 567 (18%) 325 (19%)
Sex between men and men 1,570 (51%) 899 (52%)
Injecting drug use 550 (18%) 310 (18%)
Other/unknown 391 (13%) 197 (11%)
Time between last negative and first positive HIV test (y) 0.65 0.27–1.17 0.66 0.33–1.17
Time from seroconversionb to baselinea (y) 3.96 2.34–5.98 3.43 2.03–5.35
CD4 cell count (cells/ml) at baselinea 390 252–550 524 432–696
Number of CD4 measurements between 1989 and baselinea 7 4–11 5 3–9
Estimated CD4 slope (cells/ml per year)c at baselinea 246 270 to 226 244 268 to 222
aBaseline refers to the date of the patient’s last CD4 cell count recorded in 1993.
bMidpoint between last negative and first positive test for 2,773 patients; date of laboratory evidence of seroconversion or seroconversion illness for the remaining
patients.
cPredictions from a linear mixed model with a random intercept and a random slope for the covariate time since seroconversion.
doi:10.1371/journal.pmed.1000239.t003
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year [6,8], such that cART initiation should be considered should
these thresholds be exceeded, but guidelines do not say how the
CD4 cell slope should be measured.
There are two factors that contribute to the poor prognostic
performance of the CD4 slope. First, CD4 cell slopes are often
imprecisely estimated because only few CD4 cell counts are
available per patient [1]. Second, we found strong evidence that
the rate of CD4 decline over time is nonlinear. Indeed, our more
general model based on an integrated Ornstein-Uhlenbeck process
suggests that the very concept of a constant within-patient CD4
cell decline prior to treatment is probably flawed. It would seem
that a better description of CD4 cell decline is, for each patient, a
highly variable decline over time fluctuating randomly around a
population slope. This conclusion is consistent with earlier studies
of untreated patients from the Multicenter AIDS Cohort Study
[17,18]. The fact that CD4 cell decline is not constant for each
patient but highly variable would explain why pre-cART CD4 cell
slope has so little prognostic value.
A number of studies have shown an association between CD4
cell slope with clinical outcome in the pre-cART era [1,23]. The
reported effects of CD4 cell slope in cART-naı¨ve patients were
significant but small—for example, an adjusted HR for
progression to AIDS of 1.02 for each 10 cells/ml per year
decline in CD4 cell slope [23]. We confirm the existence of such
a small effect in our supplementary analysis of 3,078 patients
from the pre-cART era but note that the effect did not reach
statistical significance in patients with a CD4 cell count
.350 cells/ml, the patient subgroup for whom a rapid CD4
decline is considered relevant under current guidelines. This
result could reflect that it is generally more difficult to predict
AIDS events or deaths in a lower-risk population of patients
with a high CD4 cell count; indeed, the prognostic ability of the
absolute CD4 cell count also decreased in this subpopulation
(but remained highly significant).
The idea that the rate of CD4 cell decline is informative seems
to have its origins in studies showing that AIDS is often preceded
by a sudden fall in CD4 cell count [24]. Such studies led some to
conclude that differences in AIDS progression rates can largely be
explained by differences in rates of CD4 cell decline [25].
However the reverse is not necessarily true—sudden falls in CD4
cell count are not always a precursor to AIDS. This was shown in
untreated patients in the early 1990s: ‘‘A more rapid long term
decline in CD4 count can be seen retrospectively to have occurred
in patients who progress to AIDS, but at any point before the
development of AIDS the near term variability precludes assigning
any prognostic significance to precipitous changes other than that
associated with a low CD4 count.’’ [24]. This message appears to
have been lost and current guidelines imply that clinicians should
consider cART for patients with a CD4 cell count above
350 cells/ml where there has been a rapid decline in CD4 cells
[6,8].
It is important to note that our study addresses a prognostic and
not a causal research question. To be specific, assume two
asymptomatic treatment-naı¨ve HIV-positive patients, both with an
identical CD4 cell count .350 cell/ml and identical other risk
factors (viral load, age, etc.) at the current assessment, but a
Table 4. Prognostic strength of CD4 slope for the prediction of clinical outcomes occurring between 1994 and 1995 in 3,078 AIDS-
free patients from the CASCADE collaboration with a CD4 cell count in 1993 and at least one prior CD4 cell count.
Outcome and Type of Summary
All Patients
(n=3,078)
Patients with .350
CD4 Cells/ml at Baseline (n=1,731)
Outcome: time to AIDS event or death
Number of events 549 (18%) 115 (7%)
Event rate per 100 patient-years of follow-up (95% CI) 10.19 (9.34–11.04) 3.57 (2.92–4.23)
Unadjusted effect of CD4 slope on outcome
HR for +10 cells/ml per year higher slope (95% CI) 0.93 (0.91–0.95); p,0.001 0.99 (0.95–1.03); p= 0.68
Discrimination (c index) 0.61 — 0.52 —
Adjusted effect of CD4 slopea
HR for +10 cells/ml per year higher slope (95% CI) 0.96 (0.94–0.98); p,0.001 0.99 (0.94–1.03); p= 0.55
Discrimination (c index) of model without CD4 slope 0.78 — 0.64 —
Discrimination (c index) of model with CD4 slope 0.78 — 0.64 —
Outcome: time to death
Number of events 237 (8%) 33 (2%)
Event rate per 100 patient-years of follow-up (95% CI) 4.14 (3.61–4.66) 1.00 (0.66–1.35)
Unadjusted effect of CD4 slope on outcome
HR for +10 cells/ml per year higher slope (95% CI) 0.93 (0.91–0.95); p,0.001 1.01 (0.94–1.10); p= 0.74
Discrimination (c index) 0.63 — 0.52 —
Adjusted effect CD4 slopea
HR for +10 cells/ml per year higher slope (95% CI) 0.99 (0.96–1.01); p= 0.28 1.01 (0.99–1.09); p= 0.73
Discrimination (c index) of model without CD4 slope 0.83 — 0.67 —
Discrimination (c index) of model with CD4 slope 0.83 — 0.66 —
CD4 slope was estimated by a linear mixed model using CD4 cell counts recorded between January 1, 1989, and December 31, 1993, with a random intercept and a
random slope for time since seroconversion.
aAdjusted for CD4 cell count, age and HIV transmission through injection drug use.
HR, hazard ratio.
doi:10.1371/journal.pmed.1000239.t004
Pre-cART CD4 Slope and Progression to AIDS
PLoS Medicine | www.plosmedicine.org 6 February 2010 | Volume 7 | Issue 2 | e1000239
different earlier CD4 dynamics, i.e., one with a steep CD4 decline
and the other with a more shallow decline. Our study assesses
whether these patients have a different prognosis. We find that the
CD4 slope is not predictive of future AIDS events or deaths if
cART is initiated immediately, i.e., both patients are expected to
have a similar outcome in this situation. Similarly, if cART is
deferred in both patients, we find no evidence that they have a
different risk of progression to AIDS while untreated. Because of
the lack of prognostic information of the CD4 cell slope in both
situations, it seems rational to ignore the CD4 slope when making
clinical decisions and, in particular, when deciding whether to
initiate cART or not.
Recent publications from cohort studies addressed the causal
question of the optimal CD4 threshold for cART initiation by
mimicking a hypothetical randomized clinical trial in their analyses
and thus avoided bias that occurs if deaths and AIDS events prior
to cART initiation or lead time are ignored [9,10]. Since it is not
possible to randomize patients to one CD4 slope or another, a
randomized clinical trial for our research question is not possible.
However, with a randomized trial one could, in principle, evaluate
explicitly whether patients with rapid CD4 progression benefit
from immediate cART treatment. To validate current treatment
guidelines related to the CD4 slope, such a trial would compare
cART initiation at a CD4 cell count of 350 cell/ml, regardless of
the rate of CD4 decline, versus cART initiation at a CD4 cell
count of 350 cells/ml combined with earlier cART initiation in
patients with a steep rate of decline. It is a limitation of our study,
that we address this causal research question only indirectly.
Importantly, however, such a trial would not answer the
question of whether the CD4 cell slope is relevant for prognosis
and medical decision making in general. Indeed, the trial may well
show the superiority of the latter treatment arm because cART
would be initiated at a higher CD4 cell count in a subgroup (i.e.,
patients with a steep decline) and earlier initiation of cART may
be beneficial regardless of the CD4 slope [10].
A further limitation of our study is that it is based on
observational cohort data and not experimental data. Although it
is unlikely, we can not rule out that patients with a steeper rate of
CD4 decline received better care than other patients and so had a
similar outcome to other patients. In addition, we include only
patients with a known date of seroconversion and our study
population may not be representative for the general population of
HIV-infected individuals. Second, it is statistically impossible to
conclude that a marker such as the CD4 slope has no effect on
clinical outcome. Our analyses were based on relatively large sample
sizes and CIs for the effect of the CD4 slope were sufficiently narrow
to rule out a large effect. However, in the subgroup of patients with
CD4 .350 cells/ml, the number of subsequent deaths was relatively
low. Third, our supplementary analysis is based on data from the
pre-cART era, i.e., 1989–1995. We are thus implicitly assuming that
current patients would have the same prognosis as patients from the
pre-cART era if cART was not initiated. Finally, we were unable to
adjust for HIV viral load in the supplementary analysis as the assays
were not generally available in the pre-cART era. However
additional adjustment for HIV-viral load would be expected to
further diminish the effect of the CD4 slope as HIV-viral load and
CD4 slope are correlated [1,11].
In conclusion, our results suggest that the prognosis of patients
with a CD4 cell count .350 cells/ml is largely unaffected by the
dynamics by which they arrived at a given CD4 cell count both if
cART is initiated or if cART is withheld. Knowledge of the
current CD4 cell count and an assessment of established risk
factors are sufficient when deciding whether to initiate cART in
asymptomatic HIV patients. The high variability of within-patient
CD4 slopes over time show that prior rates of CD4 decline cannot
be used to reliably predict a patient’s future CD4 cell count and
thus guide the CD4 cell monitoring frequency prior to cART
initiation. The implication for monitoring patients prior to starting
therapy is therefore that CD4 cell counts should be measured
regularly according to current guidelines (i.e., at least every 6 mo)
[7,8], something that may be difficult to achieve in a resource-
limited setting [26].
Supporting Information
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Editors’ Summary
Background. More than 30 million people are currently
infected with the human immunodeficiency virus (HIV), the
cause of acquired immunodeficiency syndrome (AIDS). Most
people who become infected with HIV do not become ill
immediately although some develop a short flu-like illness
shortly after infection. This illness is called ‘‘seroconversion’’
illness because it coincides with the appearance of
antibodies to HIV in the blood. The next stage of HIV
infection has no major symptoms and may last up to 10
years. During this time, HIV slowly destroys immune system
cells (including CD4 cells, a type of lymphocyte). Without
treatment, the immune system loses the ability to fight off
infections by other disease-causing organisms and HIV-
positive people then develop so-called opportunistic
infections, Kaposi sarcoma (a skin cancer), or non-Hodgkin
lymphoma (a cancer of the lymph nodes) that determine the
diagnosis of AIDS. Although HIV-positive people used to die
within 10 years of infection on average, the development in
1996 of combination antiretroviral therapy (cART; cocktails of
powerful antiretroviral drugs) means that, at least for people
living in developed countries, HIV/AIDS is now a chronic,
treatable condition.
Why Was This Study Done? The number of CD4 cells in
the blood is a strong predictor of the likelihood of AIDS or
death in untreated HIV-positive individuals and in people
starting cART. Current guidelines recommend, therefore, that
cART is started in HIV-positive patients without symptoms
when their CD4 cell count drops below a specified cutoff
level (typically 350 cells/ml.) In addition, several guidelines
suggest that clinicians should also consider cART in
symptom-free HIV-positive patients with a CD4 cell count
above the cutoff level if their CD4 cell count has rapidly
declined. However, it is not actually known whether the rate
of CD4 cell decline (so-called ‘‘CD4 slope’’) before initiating
cART is related to a patient’s outcome, so should clinicians
consider this measurement when deciding whether to
initiate cART? In this study, the researchers use data from
CASCADE (Concerted Action on SeroConversion to AIDS and
Death in Europe), a large collaborative study of 23 groups of
HIV-positive individuals whose approximate date of HIV
infection is known, to answer this question.
What Did the Researchers Do and Find? The researchers
undertook survival analyses of patients in the CASCADE
collaboration for whom at least two CD4 cell counts had
been recorded before starting cART. They calculated a pre-
cART CD4 cell count slope from these counts and used
statistical methods to investigate whether there was an
association between the rate of decline in CD4 cell count and
the time from initiating cART to the primary outcome—a first
new AIDS-defining event or death. 2820 HIV-positive
patients initiating cART were included in the study; the
average pre-cART CD4 cell decline among them was 61 cells/
ml/year. 255 of the patients experienced a new AIDS-related
event or died after starting cART but the researchers found
no evidence for an association between the primary
outcome and the pre-cART CD4 slope or between survival
and this slope. In addition, the rate of CD4 cell count decline
was not significantly associated with progression to AIDS or
death among 1731 HIV-positive, symptom-free patients with
CD4 cell counts above 350 cells/ml who were studied before
cART was developed.
What Do These Findings Mean? These findings suggest
that knowledge of the rate of CD4 cell count decline will not
improve the prediction of clinical outcome in HIV-positive
patients with a CD4 cell count above 350 cells/ml. Indeed, the
findings show that the rate of CD4 cell decline in individual
patients is highly variable over time. Consequently, a rate
measured at one time cannot be used to reliably predict a
patient’s future CD4 cell count. Because this was an
observational study, patients with the greatest rate of
decline in their CD4 cell count might have received better
care than other patients, a possibility that would lessen the
effect of the rate of CD4 cell count decline on outcomes.
Nevertheless, the findings of this study strongly suggest that
knowledge of the current CD4 cell count and an assessment
of other established risk factors for progression to AIDS are
sufficient when deciding whether to initiate cART in
symptom-free HIV-positive patients.
Additional Information. Please access these Web sites
via the online version of this summary at http://dx.doi.org/
10.1371/journal.pmed.1000239.
N Information is available from the US National Institute of
Allergy and Infectious Diseases on HIV infection and AIDS
N HIV InSite has comprehensive information on all aspects of
HIV/AIDS, including information on treatments and treat-
ment guidelines
N Information is available from Avert, an international AIDS
charity, on all aspects of HIV/AIDS, including information
on treatments for HIV and AIDS, when to start treatment,
and the stages of HIV infection (in English and Spanish)
N Information on CASCADE is available
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